Lindsay Wittman
Optometrist · Buffalo, NYNPI 1710291422
Payments from drug & device makers
Across 37 payments — averaging $49.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$475
- Bausch & Lomb Americas Inc.$290
- Sun Pharmaceutical Industries Inc.$183
- Glaukos Corporation$181
- Rayner Intraocular Lenses Limited$147
- Tarsus Pharmaceuticals, Inc.$125
- plus $429 from 7 others
What the payments were for
- Food & beverage$1,829100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 11 | $475 |
| Bausch & Lomb Americas Inc. | 5 | $290 |
| Sun Pharmaceutical Industries Inc. | 6 | $183 |
| Glaukos Corporation | 2 | $181 |
| Rayner Intraocular Lenses Limited | 1 | $147 |
| Tarsus Pharmaceuticals, Inc. | 1 | $125 |
| Sight Sciences, Inc. | 1 | $119 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $100 |
| Oyster Point Pharma, Inc. | 4 | $89 |
| Alcon | 2 | $61 |
| Biotissue Holdings Inc. | 1 | $21 |
| Dompe US, Inc. | 1 | $20 |
| Harrow Eye, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMIDRIA$147
- RayOne EMV$147
- RayOne Spheric$147
- RayOne Aspheric$147
- iDoseTR$135
- LUMIGAN$125
- COMBIGAN$125
- RESTASIS$125
- XDEMVY$125
- INFUSE$122
- OMNI$119
- ALDEN SCLERAL ZENLENS$110
- VYZULTA$100
How this compares
$1,829 in reported general payments places this provider in the 75th percentile of 2,743 optometrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cyclosporine | 20 | $15,733 |
| Prednisolone Acetate | 85 | $5,943 |
| Latanoprost | 87 | $1,677 |
| Brimonidine Tartrate | 18 | $1,607 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 54 | $762 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 22 | $711 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $633 |
| Ketorolac Tromethamine | 21 | $557 |
| Azelastine Hcl | 21 | $340 |
| Dorzolamide Hcl | 12 | $243 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Buffalo
- Andrew SaccoVestal$1.8M
- George ZikosNew York$1M
- Roy KlineLake Katrine$822K
- Irene FrantzisNew York$663K
- Daphne AmbroseNew York$509K
- Susan ResnickNew York$463K
- Murray FingeretHewlett$384K
- Albert MorierSlingerlands$347K
- Denise WhittamNew York$343K
- Justin BazanBrooklyn$304K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.